{"id":3743,"date":"2026-11-22T15:02:25","date_gmt":"2026-11-22T15:02:25","guid":{"rendered":"https:\/\/indiamedicine.org\/?p=3743"},"modified":"2026-11-22T15:02:25","modified_gmt":"2026-11-22T15:02:25","slug":"india-gsdp-rules-2026-drug-storage-distribution-guide","status":"publish","type":"post","link":"https:\/\/indiamedicine.org\/?p=3743","title":{"rendered":"India&#8217;s GSDP Rules 2026: A Guide to Drug Storage &#038; Distribution"},"content":{"rendered":"\n<li>There is a <strong>30-day public consultation window<\/strong> from the date Gazette copies are made available. Objections and suggestions go to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Kartavya Bhawan-1, New Delhi\u2013110001, or by email to the drugs division of the Ministry.<\/li>\n<li>The draft creates <strong>no separate GSDP certificate or registration process<\/strong>. It attaches guideline-compliance conditions to licences that already exist.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">What <em>does<\/em> remain enforceable is everything that exists already: the Drugs Rules, 1945 storage and licensing provisions, Schedule M where applicable, and the product-specific conditions attached to existing licences. A draft notification is not a grace period for breaching the rules that already bind you.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">&#x1f4cb; A Practical Checklist for Distributors and Buyers<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Because GSDP will attach to existing licences rather than arriving as a standalone certification, the preparation work is largely about documentation you should already be keeping. Use this list to self-audit:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Temperature records with calibration proof.<\/strong> Data loggers are worthless without calibration certificates. Cold-chain products \u2014 vaccines, insulin, biologics \u2014 need an unbroken 2\u00b0C\u20138\u00b0C record with documented excursion handling.<\/li>\n<li><strong>Written excursion and quarantine procedure.<\/strong> WHO guidance is explicit that maintaining a cold chain requires validated containers, trained personnel and strict protocols for quarantining product after a temperature breach \u2014 not simply owning a refrigerator.<\/li>\n<li><strong>Batch-level traceability both directions.<\/strong> For any batch you hold, you should be able to state where it came from and where every unit went, without manual reconstruction.<\/li>\n<li><strong>Returns, rejects and recall handling.<\/strong> GSDP explicitly covers returned, rejected, recalled and quality-suspect stock. If your returns sit in the same rack as saleable inventory, that is a finding waiting to happen.<\/li>\n<li><strong>Defined storage conditions per product.<\/strong> Not one warehouse temperature, but a documented mapping of which products require what, and where in the facility that is met.<\/li>\n<li><strong>Personnel competence records.<\/strong> Who is trained on what, with dates. Generic warehouse induction is not the same as GDP training.<\/li>\n<li><strong>Bulk drug wholesale, if applicable.<\/strong> If you deal in active or inactive bulk substances, note that G.S.R. 987(E) proposes a separate licence. The transition window is generous \u2014 the new requirements would apply on expiry of your current retention period or 12 months after final publication, whichever is later \u2014 but the licence category itself changes.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\">&#x1f3ed; The Implementation Problem Nobody Should Ignore<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">India&#8217;s distribution network is not a single system. It runs from automated metro logistics hubs to tens of thousands of small family-run wholesalers in district towns. Continuous temperature logging, climate-controlled storage and digital inventory tracking carry real capital cost, and the draft carries no economic impact assessment estimating compliance cost or the projected reduction in substandard medicines.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Enforcement capacity is the second constraint. Central and State drug inspectors gain clearer legal authority to audit warehouses, vehicles and record systems \u2014 not just factory lines \u2014 but that authority is only as good as the number of trained inspectors available to exercise it. Buyers should therefore treat GSDP as a direction of travel rather than an overnight filter: it will strengthen the audit trail over time, but it will not make every warehouse inspection-proof on day one.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">&#x2705; What This Means for Patients at the Counter<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The consumer-level benefit is narrow but real: stronger warehouse and transport oversight reduces the chance of buying heat-damaged antibiotics, inhalers or chronic-disease medicines that look intact but have lost potency. Mandatory batch traceability also makes recalls faster and more precise.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Until the rules are finalised, the practical checks remain the same ones that always mattered:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Check the expiry date before leaving the counter, not at home.<\/li>\n<li>Inspect seals and packaging for damage or evidence of re-labelling.<\/li>\n<li>Do not store medicines in bathrooms or in a car \u2014 heat and humidity degrade formulations.<\/li>\n<li>Carry insulin or vaccines home in an insulated pack, not a handbag.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">For patients buying from overseas suppliers, a distributor&#8217;s ability to produce temperature records and two-way batch traceability is a far better quality signal than any marketing claim. For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">&#x1f4cc; Summary<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>What:<\/strong> Draft amendment G.S.R. 984(E) to the Drugs Rules, 1945, adding GSDP compliance as a licence condition across nine provisions.<\/li>\n<li><strong>Status:<\/strong> Draft, under 30-day public consultation. Not enforceable yet. No separate certificate.<\/li>\n<li><strong>Who:<\/strong> Manufacturers, importers, wholesalers, retailers, repackers and specified licensed establishments.<\/li>\n<li><strong>Action now:<\/strong> Audit temperature records, calibration, two-way traceability, returns segregation and staff training \u2014 all of which you should already have.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Sources: Ministry of Health and Family Welfare draft gazette notifications G.S.R. 984(E), 985(E) and 987(E) (November 2026); PIB Delhi release of 19 November 2026; WHO Technical Report Series No. 1025 (Annex 7, 2020) and No. 1067 (2026); CDSCO Good Distribution Practices draft guidelines (August 2024); reporting by Express Pharma, The New Indian Express and Indian Pharma Post (19\u201320 November 2026).<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:list-item -->\n<ul>\n<!-- wp:list-item --><li>The notification is a <strong>draft<\/strong>. Enforceability begins only on final publication, on a date the government will specify at that time.<\/li><!-- wp:list-item -->\n<!-- wp:list-item --><li>There is a <strong>30-day public consultation window<\/strong> from the date Gazette copies are made available. Objections and suggestions go to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Kartavya Bhawan-1, New Delhi\u2013110001, or by email to the drugs division of the Ministry.<\/li><!-- wp:list-item -->\n<!-- wp:list-item --><li>The draft creates <strong>no separate GSDP certificate or registration process<\/strong>. It attaches guideline-compliance conditions to licences that already exist.<\/li><!-- \/wp:list-item -->\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:paragraph -->\n<p>What <em>does<\/em> remain enforceable is everything that exists already: the Drugs Rules, 1945 storage and licensing provisions, Schedule M where applicable, and the product-specific conditions attached to existing licences. A draft notification is not a grace period for breaching the rules that already bind you.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">&#x1f4cb; A Practical Checklist for Distributors and Buyers<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Because GSDP will attach to existing licences rather than arriving as a standalone certification, the preparation work is largely about documentation you should already be keeping. Use this list to self-audit:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list {\"ordered\":true} -->\n<ol>\n<!-- wp:list-item --><li><strong>Temperature records with calibration proof.<\/strong> Data loggers are worthless without calibration certificates. Cold-chain products \u2014 vaccines, insulin, biologics \u2014 need an unbroken 2\u00b0C\u20138\u00b0C record with documented excursion handling.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Written excursion and quarantine procedure.<\/strong> WHO guidance is explicit that maintaining a cold chain requires validated containers, trained personnel and strict protocols for quarantining product after a temperature breach \u2014 not simply owning a refrigerator.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Batch-level traceability both directions.<\/strong> For any batch you hold, you should be able to state where it came from and where every unit went, without manual reconstruction.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Returns, rejects and recall handling.<\/strong> GSDP explicitly covers returned, rejected, recalled and quality-suspect stock. If your returns sit in the same rack as saleable inventory, that is a finding waiting to happen.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Defined storage conditions per product.<\/strong> Not one warehouse temperature, but a documented mapping of which products require what, and where in the facility that is met.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Personnel competence records.<\/strong> Who is trained on what, with dates. Generic warehouse induction is not the same as GDP training.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Bulk drug wholesale, if applicable.<\/strong> If you deal in active or inactive bulk substances, note that G.S.R. 987(E) proposes a separate licence. The transition window is generous \u2014 the new requirements would apply on expiry of your current retention period or 12 months after final publication, whichever is later \u2014 but the licence category itself changes.<\/li><!-- \/wp:list-item -->\n<\/ol>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">&#x1f3ed; The Implementation Problem Nobody Should Ignore<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>India&#8217;s distribution network is not a single system. It runs from automated metro logistics hubs to tens of thousands of small family-run wholesalers in district towns. Continuous temperature logging, climate-controlled storage and digital inventory tracking carry real capital cost, and the draft carries no economic impact assessment estimating compliance cost or the projected reduction in substandard medicines.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>Enforcement capacity is the second constraint. Central and State drug inspectors gain clearer legal authority to audit warehouses, vehicles and record systems \u2014 not just factory lines \u2014 but that authority is only as good as the number of trained inspectors available to exercise it. Buyers should therefore treat GSDP as a direction of travel rather than an overnight filter: it will strengthen the audit trail over time, but it will not make every warehouse inspection-proof on day one.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">&#x2705; What This Means for Patients at the Counter<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The consumer-level benefit is narrow but real: stronger warehouse and transport oversight reduces the chance of buying heat-damaged antibiotics, inhalers or chronic-disease medicines that look intact but have lost potency. Mandatory batch traceability also makes recalls faster and more precise.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>Until the rules are finalised, the practical checks remain the same ones that always mattered:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul>\n<!-- wp:list-item --><li>Check the expiry date before leaving the counter, not at home.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li>Inspect seals and packaging for damage or evidence of re-labelling.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li>Do not store medicines in bathrooms or in a car \u2014 heat and humidity degrade formulations.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li>Carry insulin or vaccines home in an insulated pack, not a handbag.<\/li><!-- \/wp:list-item -->\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:paragraph -->\n<p>For patients buying from overseas suppliers, a distributor&#8217;s ability to produce temperature records and two-way batch traceability is a far better quality signal than any marketing claim. For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n<!-- \/wp:separator -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">&#x1f4cc; Summary<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:list -->\n<ul>\n<!-- wp:list-item --><li><strong>What:<\/strong> Draft amendment G.S.R. 984(E) to the Drugs Rules, 1945, adding GSDP compliance as a licence condition across nine provisions.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Status:<\/strong> Draft, under 30-day public consultation. Not enforceable yet. No separate certificate.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Who:<\/strong> Manufacturers, importers, wholesalers, retailers, repackers and specified licensed establishments.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Action now:<\/strong> Audit temperature records, calibration, two-way traceability, returns segregation and staff training \u2014 all of which you should already have.<\/li><!-- \/wp:list-item -->\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:paragraph -->\n<p><em>Sources: Ministry of Health and Family Welfare draft gazette notifications G.S.R. 984(E), 985(E) and 987(E) (November 2026); PIB Delhi release of 19 November 2026; WHO Technical Report Series No. 1025 (Annex 7, 2020) and No. 1067 (2026); CDSCO Good Distribution Practices draft guidelines (August 2024); reporting by Express Pharma, The New Indian Express and Indian Pharma Post (19\u201320 November 2026).<\/em><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:post-content --><!-- \/wp:list-item -->\n\n<!-- wp:list -->\n<ul>\n<!-- wp:list-item --><li>The notification is a <strong>draft<\/strong>. Enforceability begins only on final publication, on a date the government will specify at that time.<\/li><!-- wp:list-item -->\n<!-- wp:list-item --><li>There is a <strong>30-day public consultation window<\/strong> from the date Gazette copies are made available. Objections and suggestions go to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Kartavya Bhawan-1, New Delhi\u2013110001, or by email to the drugs division of the Ministry.<\/li><!-- wp:list-item -->\n<!-- wp:list-item --><li>The draft creates <strong>no separate GSDP certificate or registration process<\/strong>. It attaches guideline-compliance conditions to licences that already exist.<\/li><!-- \/wp:list-item -->\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:paragraph -->\n<p>What <em>does<\/em> remain enforceable is everything that exists already: the Drugs Rules, 1945 storage and licensing provisions, Schedule M where applicable, and the product-specific conditions attached to existing licences. A draft notification is not a grace period for breaching the rules that already bind you.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">&#x1f4cb; A Practical Checklist for Distributors and Buyers<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Because GSDP will attach to existing licences rather than arriving as a standalone certification, the preparation work is largely about documentation you should already be keeping. Use this list to self-audit:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list {\"ordered\":true} -->\n<ol>\n<!-- wp:list-item --><li><strong>Temperature records with calibration proof.<\/strong> Data loggers are worthless without calibration certificates. Cold-chain products \u2014 vaccines, insulin, biologics \u2014 need an unbroken 2\u00b0C\u20138\u00b0C record with documented excursion handling.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Written excursion and quarantine procedure.<\/strong> WHO guidance is explicit that maintaining a cold chain requires validated containers, trained personnel and strict protocols for quarantining product after a temperature breach \u2014 not simply owning a refrigerator.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Batch-level traceability both directions.<\/strong> For any batch you hold, you should be able to state where it came from and where every unit went, without manual reconstruction.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Returns, rejects and recall handling.<\/strong> GSDP explicitly covers returned, rejected, recalled and quality-suspect stock. If your returns sit in the same rack as saleable inventory, that is a finding waiting to happen.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Defined storage conditions per product.<\/strong> Not one warehouse temperature, but a documented mapping of which products require what, and where in the facility that is met.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Personnel competence records.<\/strong> Who is trained on what, with dates. Generic warehouse induction is not the same as GDP training.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Bulk drug wholesale, if applicable.<\/strong> If you deal in active or inactive bulk substances, note that G.S.R. 987(E) proposes a separate licence. The transition window is generous \u2014 the new requirements would apply on expiry of your current retention period or 12 months after final publication, whichever is later \u2014 but the licence category itself changes.<\/li><!-- \/wp:list-item -->\n<\/ol>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">&#x1f3ed; The Implementation Problem Nobody Should Ignore<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>India&#8217;s distribution network is not a single system. It runs from automated metro logistics hubs to tens of thousands of small family-run wholesalers in district towns. Continuous temperature logging, climate-controlled storage and digital inventory tracking carry real capital cost, and the draft carries no economic impact assessment estimating compliance cost or the projected reduction in substandard medicines.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>Enforcement capacity is the second constraint. Central and State drug inspectors gain clearer legal authority to audit warehouses, vehicles and record systems \u2014 not just factory lines \u2014 but that authority is only as good as the number of trained inspectors available to exercise it. Buyers should therefore treat GSDP as a direction of travel rather than an overnight filter: it will strengthen the audit trail over time, but it will not make every warehouse inspection-proof on day one.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">&#x2705; What This Means for Patients at the Counter<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The consumer-level benefit is narrow but real: stronger warehouse and transport oversight reduces the chance of buying heat-damaged antibiotics, inhalers or chronic-disease medicines that look intact but have lost potency. Mandatory batch traceability also makes recalls faster and more precise.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>Until the rules are finalised, the practical checks remain the same ones that always mattered:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul>\n<!-- wp:list-item --><li>Check the expiry date before leaving the counter, not at home.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li>Inspect seals and packaging for damage or evidence of re-labelling.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li>Do not store medicines in bathrooms or in a car \u2014 heat and humidity degrade formulations.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li>Carry insulin or vaccines home in an insulated pack, not a handbag.<\/li><!-- \/wp:list-item -->\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:paragraph -->\n<p>For patients buying from overseas suppliers, a distributor&#8217;s ability to produce temperature records and two-way batch traceability is a far better quality signal than any marketing claim. For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n<!-- \/wp:separator -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">&#x1f4cc; Summary<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:list -->\n<ul>\n<!-- wp:list-item --><li><strong>What:<\/strong> Draft amendment G.S.R. 984(E) to the Drugs Rules, 1945, adding GSDP compliance as a licence condition across nine provisions.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Status:<\/strong> Draft, under 30-day public consultation. Not enforceable yet. No separate certificate.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Who:<\/strong> Manufacturers, importers, wholesalers, retailers, repackers and specified licensed establishments.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Action now:<\/strong> Audit temperature records, calibration, two-way traceability, returns segregation and staff training \u2014 all of which you should already have.<\/li><!-- \/wp:list-item -->\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:paragraph -->\n<p><em>Sources: Ministry of Health and Family Welfare draft gazette notifications G.S.R. 984(E), 985(E) and 987(E) (November 2026); PIB Delhi release of 19 November 2026; WHO Technical Report Series No. 1025 (Annex 7, 2020) and No. 1067 (2026); CDSCO Good Distribution Practices draft guidelines (August 2024); reporting by Express Pharma, The New Indian Express and Indian Pharma Post (19\u201320 November 2026).<\/em><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:post-content --><!-- \/wp:list --><!-- wp:post-content --><!-- wp:paragraph -->\n<p>India has regulated how medicines are <em>made<\/em> for decades. What happens to them after they leave the factory gate has been far less tightly controlled. On 19 November 2026, the Union Ministry of Health and Family Welfare moved to close that gap by proposing Good Storage and Distribution Practices (GSDP) as a binding condition of the drug licence itself. For anyone who buys, imports, stores or distributes medicines in India, this is the most consequential supply-chain change since the revised Schedule M.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>This guide explains what the draft actually says, what is enforceable today versus what is merely proposed, and what buyers and distributors should check before the rules are finalised.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">&#x1f4dc; What the Government Actually Proposed<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Three separate draft notifications were published by the Ministry in November 2026, and they are routinely conflated in press coverage. They are not the same instrument:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul>\n<!-- wp:list-item --><li><strong>G.S.R. 984(E)<\/strong>, dated 4 November 2026 and published in the Gazette of India dated 12 November 2026 \u2014 the GSDP amendment. It proposes inserting GSDP compliance as an express licence condition into <strong>nine<\/strong> existing provisions of the Drugs Rules, 1945 (Rules 2, 26, 33A, 65, 74, 74A, 74B, 78, 78A and 122P).<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>G.S.R. 987(E)<\/strong>, dated 2 November 2026 \u2014 a separate wholesale licence framework for bulk drugs, with a new application form (Form 19-BC) and licence form (Form 20-BC), carving bulk drugs out of the common formulation wholesale licence.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>G.S.R. 985(E)<\/strong> \u2014 a targeted relaxation of revised Schedule M requirements for medicinal gases, empty gelatin capsules and disinfectant fluids, following a recommendation of the 93rd meeting of the Drugs Technical Advisory Board (DTAB) on 16 February 2026.<\/li><!-- \/wp:list-item -->\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:paragraph -->\n<p>The GSDP proposal is legally grounded in Sections 12(1) and 33(1) of the Drugs and Cosmetics Act, 1940, and references CDSCO&#8217;s Good Distribution Practices guidelines, which were first circulated in draft form in August 2024 and have until now operated as advisory guidance rather than enforceable conditions.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">&#x2696;&#xfe0f; GDP vs GSDP vs GMP: Why the Distinction Matters<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>These three acronyms appear interchangeably in industry conversation, but they govern different activities \u2014 and only two of them affect what happens to a medicine after it is released for sale.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul>\n<!-- wp:list-item --><li><strong>GMP (Good Manufacturing Practices)<\/strong> \u2014 controls the factory: premises, equipment, production processes, quality control systems. The revised Schedule M brought this into line with WHO-GMP expectations.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>GDP (Good Distribution Practices)<\/strong> \u2014 protects product quality and identity across the distribution process, including the storage activities inside it.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>GSDP (Good Storage and Distribution Practices)<\/strong> \u2014 the term used in the November 2026 draft, covering storage conditions, transport, inventory, documentation, returns and recalls, and staff competence.<\/li><!-- \/wp:list-item -->\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:paragraph -->\n<p>The key point for buyers: a manufacturer holding a valid GMP-compliant licence tells you the batch was made correctly. It tells you nothing about whether the consignment spent six hours on a loading dock in Nagpur in May. GSDP is the instrument that reaches that part of the chain.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">&#x1f321;&#xfe0f; The Six Risks the Framework Targets<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The GSDP structure follows the risk categories long used by the World Health Organization in its technical guidance on storage and transport of time- and temperature-sensitive pharmaceutical products (WHO Technical Report Series No. 1025, Annex 7, 2020, and TRS No. 1067, 2026):<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list {\"ordered\":true} -->\n<ol>\n<!-- wp:list-item --><li><strong>Deterioration<\/strong> \u2014 chemical breakdown from heat, moisture or light exposure.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Contamination<\/strong> \u2014 compromised packaging or unsanitary warehouse conditions.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Mix-ups<\/strong> \u2014 poor labelling leading to the wrong batch or product reaching a counter.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Falsification<\/strong> \u2014 weak oversight allowing counterfeit product into the legitimate network.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Diversion<\/strong> \u2014 authorised stock redirected into unapproved markets.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Loss of traceability<\/strong> \u2014 missing records that prevent a batch being located during a recall.<\/li><!-- \/wp:list-item -->\n<\/ol>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">&#x1f50d; What Is Actually Enforceable Today \u2014 and What Is Not<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>This is where most coverage overreaches. As of November 2026, the GSDP draft is <strong>not law<\/strong>. Three facts define its current status:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul>\n<!-- wp:list-item --><li>The notification is a <strong>draft<\/strong>. Enforceability begins only on final publication, on a date the government will specify at that time.<\/li><!-- wp:list-item -->\n<!-- wp:list-item --><li>There is a <strong>30-day public consultation window<\/strong> from the date Gazette copies are made available. Objections and suggestions go to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Kartavya Bhawan-1, New Delhi\u2013110001, or by email to the drugs division of the Ministry.<\/li><!-- wp:list-item -->\n<!-- wp:list-item --><li>The draft creates <strong>no separate GSDP certificate or registration process<\/strong>. It attaches guideline-compliance conditions to licences that already exist.<\/li><!-- \/wp:list-item -->\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:paragraph -->\n<p>What <em>does<\/em> remain enforceable is everything that exists already: the Drugs Rules, 1945 storage and licensing provisions, Schedule M where applicable, and the product-specific conditions attached to existing licences. A draft notification is not a grace period for breaching the rules that already bind you.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">&#x1f4cb; A Practical Checklist for Distributors and Buyers<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Because GSDP will attach to existing licences rather than arriving as a standalone certification, the preparation work is largely about documentation you should already be keeping. Use this list to self-audit:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list {\"ordered\":true} -->\n<ol>\n<!-- wp:list-item --><li><strong>Temperature records with calibration proof.<\/strong> Data loggers are worthless without calibration certificates. Cold-chain products \u2014 vaccines, insulin, biologics \u2014 need an unbroken 2\u00b0C\u20138\u00b0C record with documented excursion handling.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Written excursion and quarantine procedure.<\/strong> WHO guidance is explicit that maintaining a cold chain requires validated containers, trained personnel and strict protocols for quarantining product after a temperature breach \u2014 not simply owning a refrigerator.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Batch-level traceability both directions.<\/strong> For any batch you hold, you should be able to state where it came from and where every unit went, without manual reconstruction.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Returns, rejects and recall handling.<\/strong> GSDP explicitly covers returned, rejected, recalled and quality-suspect stock. If your returns sit in the same rack as saleable inventory, that is a finding waiting to happen.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Defined storage conditions per product.<\/strong> Not one warehouse temperature, but a documented mapping of which products require what, and where in the facility that is met.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Personnel competence records.<\/strong> Who is trained on what, with dates. Generic warehouse induction is not the same as GDP training.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Bulk drug wholesale, if applicable.<\/strong> If you deal in active or inactive bulk substances, note that G.S.R. 987(E) proposes a separate licence. The transition window is generous \u2014 the new requirements would apply on expiry of your current retention period or 12 months after final publication, whichever is later \u2014 but the licence category itself changes.<\/li><!-- \/wp:list-item -->\n<\/ol>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">&#x1f3ed; The Implementation Problem Nobody Should Ignore<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>India&#8217;s distribution network is not a single system. It runs from automated metro logistics hubs to tens of thousands of small family-run wholesalers in district towns. Continuous temperature logging, climate-controlled storage and digital inventory tracking carry real capital cost, and the draft carries no economic impact assessment estimating compliance cost or the projected reduction in substandard medicines.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>Enforcement capacity is the second constraint. Central and State drug inspectors gain clearer legal authority to audit warehouses, vehicles and record systems \u2014 not just factory lines \u2014 but that authority is only as good as the number of trained inspectors available to exercise it. Buyers should therefore treat GSDP as a direction of travel rather than an overnight filter: it will strengthen the audit trail over time, but it will not make every warehouse inspection-proof on day one.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">&#x2705; What This Means for Patients at the Counter<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The consumer-level benefit is narrow but real: stronger warehouse and transport oversight reduces the chance of buying heat-damaged antibiotics, inhalers or chronic-disease medicines that look intact but have lost potency. Mandatory batch traceability also makes recalls faster and more precise.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>Until the rules are finalised, the practical checks remain the same ones that always mattered:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul>\n<!-- wp:list-item --><li>Check the expiry date before leaving the counter, not at home.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li>Inspect seals and packaging for damage or evidence of re-labelling.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li>Do not store medicines in bathrooms or in a car \u2014 heat and humidity degrade formulations.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li>Carry insulin or vaccines home in an insulated pack, not a handbag.<\/li><!-- \/wp:list-item -->\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:paragraph -->\n<p>For patients buying from overseas suppliers, a distributor&#8217;s ability to produce temperature records and two-way batch traceability is a far better quality signal than any marketing claim. For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n<!-- \/wp:separator -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">&#x1f4cc; Summary<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:list -->\n<ul>\n<!-- wp:list-item --><li><strong>What:<\/strong> Draft amendment G.S.R. 984(E) to the Drugs Rules, 1945, adding GSDP compliance as a licence condition across nine provisions.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Status:<\/strong> Draft, under 30-day public consultation. Not enforceable yet. No separate certificate.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Who:<\/strong> Manufacturers, importers, wholesalers, retailers, repackers and specified licensed establishments.<\/li><!-- \/wp:list-item -->\n<!-- wp:list-item --><li><strong>Action now:<\/strong> Audit temperature records, calibration, two-way traceability, returns segregation and staff training \u2014 all of which you should already have.<\/li><!-- \/wp:list-item -->\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:paragraph -->\n<p><em>Sources: Ministry of Health and Family Welfare draft gazette notifications G.S.R. 984(E), 985(E) and 987(E) (November 2026); PIB Delhi release of 19 November 2026; WHO Technical Report Series No. 1025 (Annex 7, 2020) and No. 1067 (2026); CDSCO Good Distribution Practices draft guidelines (August 2024); reporting by Express Pharma, The New Indian Express and Indian Pharma Post (19\u201320 November 2026).<\/em><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:post-content -->","protected":false},"excerpt":{"rendered":"<p>There is a 30-day public consultation window from the date Gazette copies are made available. Objections and suggestions go to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Kartavya Bhawan-1, New Delhi\u2013110001, or by email to the drugs division of the Ministry. The draft creates no separate GSDP certificate or registration process. It [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[42,48,43,29,49],"class_list":["post-3743","post","type-post","status-publish","format-standard","hentry","category-knowledge","tag-cdsco","tag-generic-medicines","tag-import-guides","tag-india-pharmacy","tag-indian-pharma","entry"],"_links":{"self":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3743"}],"version-history":[{"count":0,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3743\/revisions"}],"wp:attachment":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}